
Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost
Exeliom Biosciences (Paris, France) is using its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies....

BioSenic halts ALLOB development
ALLOB was developed before the US$40.8m majority buyout of Bone Therapeutics by French Medsenic SAS last October. Before the reverse merger, in...

Alnylam in US$2.8bn biobucks deal with Roche
The deal, which could fetch Alnylam Pharmaceuticals Inc up to US$2.8bn if all milestones are met and marketing approval is granted, clearly marks Big...

Nanobiotix SA licences NBTXR3 to J&J
NBTXR3 is currently being evaluated across different solid tumour indications including NANORAY‑312, a global Phase III pivotal study in ...

Pierre Fabre Laboratories acquires Vertical Bio
The acquisition of Vertical Bio AG for an undisclosed amount of money allows Pierre Fabre Laboratories to...

Enzyme foams morer active and stable
So far, foamed enzymes changed their structure and thus function. However, the new method, for which a patent has been filed circumvents this...

Oxford Biomedica expands agreement with Cabaletta Bio
Philadelphia-based clinical-stage biotech Cabaletta Bio focuses on developing and launching the first curative targeted cell therapies for patients...